Last reviewed · How we verify
Seloken ZOK/Toprol-XL
Seloken ZOK/Toprol-XL is a beta-blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline, and slowing the heart rate and reducing its workload.
Seloken ZOK/Toprol-XL is a beta-blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline, and slowing the heart rate and reducing its workload. Used for Hypertension, Angina pectoris, Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Seloken ZOK/Toprol-XL |
|---|---|
| Also known as | Toprol-XL |
| Sponsor | AstraZeneca |
| Drug class | beta-blocker |
| Target | beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This is achieved by blocking the action of epinephrine on beta-1 receptors in the heart, which reduces the heart rate and the force of contraction. This leads to a decrease in blood pressure and a reduction in the workload of the heart.
Approved indications
- Hypertension
- Angina pectoris
- Atrial fibrillation for stroke prevention
Common side effects
- Dizziness
- Fatigue
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life (PHASE4)
- Reversal of Ventricular Remodeling With Toprol-XL (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Seloken ZOK/Toprol-XL CI brief — competitive landscape report
- Seloken ZOK/Toprol-XL updates RSS · CI watch RSS
- AstraZeneca portfolio CI